Our analysis revealed a distinct immune profile between MRD+ and MRD– patients, with the latter showing a more experienced adaptive immunity (i.e., CD4+ and CD8+ T cells) phenotype, probably indicative of competent immune surveillance keeping myeloma burden in repression. Here, CD4 is linked to plasma cell myeloma.